Damian Muszak

Dr. Damian Muszak

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2019 in Molecules
Verified
Journal Article
Open access
PDF file
KGKatarzyna Guzik
Katarzyna Guzik
MTMarcin Tomala
Marcin Tomala
DMDamian Muszak
Damian Muszak
MKMagdalena Konieczny
Magdalena Konieczny
AHAleksandra Hec
Aleksandra Hec
THTad Holak
Tad Holak
Cancer immunotherapy based on antibodies targeting the immune checkpoint PD-1/PD-L1 pathway has seen unprecedented clinical responses and constitutes the new paradigm in cancer therapy. The antibody-based immunotherapies have several limitations such as high production cost of the antibodies or their long half-life. Small-molecule inhibitors of the PD-1/PD-L1 interaction have been highly anticipated as a promising alternative or complementary therapeutic to the monoclonal antibodies (mAbs). Currently, the field of developing anti-PD-1/PD-L1 small-molecule inhibitors is intensively explored. In this paper, we review anti-PD-1/PD-L1 small-molecule and peptide-based inhibitors and discuss recent structural and preclinical/clinical aspects of their development. Discovery of the therapeutics based on small-molecule inhibitors of the PD-1/PD-L1 interaction represents a promising but challenging perspective in cancer treatment.

27 July 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
DMDamian Muszak
Damian Muszak
ESEwa Surmiak
Ewa Surmiak
JPJacek Plewka
Jacek Plewka
KMKatarzyna Magiera-Mularz
Katarzyna Magiera-Mularz
JKJustyna Kocik
Justyna Kocik
THTad Holak
Tad Holak
We describe a new class of potent PD-L1/PD-1 inhibitors based on a terphenyl scaffold that is derived from the rigidified biphenyl-inspired structure. Using in silico docking, we designed and then experimentally demonstrated the effectiveness of the terphenyl-based scaffolds in inhibiting PD-1/PD-L1 complex formation using various biophysical and biochemical techniques. We also present a high-resolution structure of the complex of PD-L1 with one of our most potent inhibitors to identify key PD-L1/inhibitor interactions at the molecular level. In addition, we show the efficacy of our most potent inhibitors in activating the antitumor response using primary human immune cells from healthy donors.

Verified
Journal Article
Open access
PDF file
ESEwa Surmiak
Ewa Surmiak
KMKatarzyna Magiera-Mularz
Katarzyna Magiera-Mularz
BMBogdan Musielak
Bogdan Musielak
DMDamian Muszak
Damian Muszak
JKJustyna Kocik
Justyna Kocik
LSLukasz Skalniak
Lukasz Skalniak
Targeting the programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) interaction has become an established strategy for cancer immunotherapy. Although hundreds of small-molecule, peptide, and peptidomimetic inhibitors have been proposed in recent years, only a limited number of drug candidates show good PD-1/PD-L1 blocking activity in cell-based assays. In this article, we compare representative molecules from different classes in terms of their PD-1/PD-L1 dissociation capacity measured by HTRF and in vitro bioactivity determined by the immune checkpoint blockade (ICB) co-culture assay. We point to recent discoveries that underscore important differences in the mechanisms of action of these molecules and also indicate one principal feature that needs to be considered, which is the eventual human PD-L1 specificity.

8 September 2022 in ACS Chemical Biology
Verified
Journal Article
Open access
RKRadoslaw Kitel
Radoslaw Kitel
IRIsmael Alejandro Rodriguez
Ismael Alejandro Rodriguez
XCXabier del Corte
Xabier del Corte
JAJack Atmaj
Jack Atmaj
MŻMagdalena Żarnik
Magdalena Żarnik
BMBogdan Musielak
Bogdan Musielak
Development of small molecules targeting the PD-L1/PD-1 interface is advancing both in industry and academia, but only a few have reached early-stage clinical trials. Here, we take a closer look at the general druggability of PD-L1 using in silico hot spot mapping and nuclear magnetic resonance (NMR)-based characterization. We found that the conformational elasticity of the PD-L1 surface strongly influences the formation of hot spots. We deconstructed several generations of known inhibitors into fragments and examined their binding properties using differential scanning fluorimetry (DSF) and protein-based nuclear magnetic resonance (NMR). These biophysical analyses showed that not all fragments bind to the PD-L1 ectodomain despite having the biphenyl scaffold. Although most of the binding fragments induced PD-L1 oligomerization, two compounds, TAH35 and TAH36, retain the monomeric state of proteins upon binding. Additionally, the presence of the entire ectodomain did not affect the binding of the hit compounds and dimerization of PD-L1. The data demonstrated here provide important information on the PD-L1 druggability and the structure-activity relationship of the biphenyl core moiety and therefore may aid in the design of novel inhibitors and focused fragment libraries for PD-L1.

4 June 2024 in Molecules
Verified
Journal Article
Open access
PDF file
JKJoanna Klimek
Joanna Klimek
OKOskar Kruc
Oskar Kruc
JCJoanna Ceklarz
Joanna Ceklarz
BKBeata Kamińska
Beata Kamińska
BMBogdan Musielak
Bogdan Musielak
ESEwa Surmiak
Ewa Surmiak
The PD-1/PD-L1 complex is an immune checkpoint responsible for regulating the natural immune response, but also allows tumors to escape immune surveillance. Inhibition of the PD-1/PD-L1 axis positively contributes to the efficacy of cancer treatment. The only available therapeutics targeting PD-1/PD-L1 are monoclonal antibody-based drugs, which have several limitations. Therefore, small molecule compounds are emerging as an attractive alternative that can potentially overcome the drawbacks of mAb-based therapy. In this article, we present a novel class of small molecule compounds based on the terphenyl scaffold that bind to PD-L1. The general architecture of the presented structures is characterized by axial symmetry and consists of three elements: an m-terphenyl core, an additional aromatic ring, and a solubilizing agent. Using molecular docking, we designed a series of final compounds, which were subsequently synthesized and tested in HTRF assay and NMR binding assay to evaluate their activity. In addition, we performed an in-depth analysis of the mutual arrangement of the phenyl rings of the terphenyl core within the binding pocket of PD-L1 and found several correlations between the plane angle values and the affinity of the compounds towards the protein.

1 November 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CNConstantinos G. Neochoritis
Constantinos G. Neochoritis
JAJack Atmaj
Jack Atmaj
Aleksandra Twarda-ClapaAleksandra Twarda-Clapa
Aleksandra Twarda-Clapa
ESEwa Surmiak
Ewa Surmiak
LSLukasz Skalniak
Lukasz Skalniak
ADAlexander Dömling
Alexander Dömling